Russ Cohen

CG Oncology Files for Proposed $100M IPO CG Oncology Spearheads $100M IPO Filing

Initial public offering hologram, night panoramic city view of Bangkok. The financial center for multinational corporations in Asia. The concept of boosting the growth by IPO process. Double exposure.

2d illustrations and photos

CG Oncology (CGON) has initiated steps to raise approximately $100M through an initial public offering.

Without specifying any terms in its SEC filing, the biotech company has shown interest in raising around $100M. However, this number is likely a placeholder and subject to change.

The company aims to list its shares on Nasdaq under the symbol CGON, with Morgan Stanley, Goldman Sachs, Cantor, and LifeSci Capital acting as underwriters.

Based in California, CG Oncology is focused on developing a bladder-sparing therapy for patients with bladder cancer, with its lead drug candidate, cretostimogene, currently in Phase 3 testing.

See also  The Driving Forces Behind Bitcoin’s Rally Unveiled by Financial Icon